MRNA vs VRTX: How Moderna and Vertex Pharmaceuticals Compare (2026)

Same yardstick, side by side (as of July 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. MRNA and VRTX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined MRNA and VRTX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Moderna is a Cambridge, Massachusetts biotechnology company built entirely around messenger RNA (mRNA) technology, the platform behind its Spikevax COVID-19 vaccine. After generating enormous pandemic-era revenue, demand has fallen sharply, and the company is trying to broaden beyond COVID into a wider vaccine and therapeutics franchise. Its approved and near-market products include Spikevax, the mRESVIA RSV vaccine for older adults, and newer respiratory approvals in Europe (mNEXSPIKE and the mCOMBRIAX combination shot), while its most watched late-stage assets are the mRNA-1010 seasonal flu vaccine and intismeran autogene (mRNA-4157), a personalized cancer vaccine developed with Merck.

Full MRNA guide

Vertex Pharmaceuticals is a Boston-based biotechnology company that designs medicines targeting the root molecular cause of serious diseases rather than only their symptoms. Its foundation is cystic fibrosis (CF), a genetic disease in which a defective CFTR protein disrupts salt and water movement in cells, damaging the lungs and other organs. Vertex developed the first drugs that correct the underlying protein defect, progressing from Kalydeco to Orkambi and Symdeko and then to the breakthrough triple-combination Trikafta (marketed as Kaftrio in Europe), which treats the large majority of CF patients. In late 2024 it began rolling out Alyftrek, a next-generation once-daily successor designed to extend that franchise and its patent protection. Because CF is a rare disease with essentially no competing root-cause therapy, Vertex has enjoyed pricing power and durable, high-margin revenue.

Full VRTX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• MRNA drivers: Respiratory franchise beyond COVID; Oncology optionality via Merck partnership.
• VRTX drivers: A durable, high-margin cystic fibrosis near-monopoly; Journavx opens a large non-opioid pain market.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs. For VRTX, the central risk is revenue concentration: cystic fibrosis still accounts for the overwhelming majority of Vertex's sales, so any disruption, whether a safety signal, a competing modulator, or pricing pressure, would hit the core disproportionately, and the newer products remain small by comparison.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick MRNA if you believe its drivers more; VRTX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the MRNA and VRTX guides.

MRNA. MRNA trades on pipeline potential rather than current earnings, since it is loss-making with revenue far below its pandemic peak. Traditional multiples like P/E are not meaningful while the company is unprofitable, so the market is effectively pricing the odds of flu, combination, and cancer-vaccine programs succeeding. The multibillion-dollar cash balance is a key reason the company can fund that pipeline toward its 2028 break-even goal.

VRTX. Vertex trades at a premium to the large-cap pharma average, with a trailing P/E near the high 20s and a forward P/E around 25, reflecting both its high margins and near-monopoly economics in cystic fibrosis and the market's expectation that the pain, cell-therapy, and pipeline programs will add a second and third growth engine. Because the CF franchise is so profitable and the balance sheet holds substantial net cash, much of the valuation debate is about how much credit to give unproven pipeline assets. Vertex does not pay a dividend, so returns depend entirely on earnings growth and multiple, which makes clinical and launch execution the key swing factors.

Headline figures (approximate, July 2026): MRNA shows market cap ~$20 billion, q1 2026 revenue ~$400 million, q1 2026 net loss ~$1.3 billion (incl. ~$878M legal charge), 2026 revenue growth guidance up to ~10%; VRTX shows revenue (fy 2025) ~$12.0 billion, revenue growth (fy 2025) ~9%, revenue guidance (fy 2026) ~$12.95 billion to $13.1 billion, trailing p/e (approx.) ~29x.

MRNA and VRTX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined MRNA and VRTX exposure against your real portfolio. It is not an investment adviser.